Companies / AI company
Pathos AI
An AI drug developer; licenses de-identified neurology records from Tempus AI. Recorded here: 1 disclosed licensing deal and 1 public price.
pathos.comLatest record 23 Oct 2026
licensing deals
Public prices involving Pathos AI
- De-identified records of patients with Alzheimer's disease or other neurological conditions, 500,000 records over five years (100,000 a year), licensed by Tempus AI to Pathos AI with sublicence to Bristol Myers Squibb
A realised licence disclosed in the licensor's SEC filing: Tempus aggregates records from care providers and licenses them on; a further $5.0 million pays for record updates. Exclusive for 18 months after each delivery (see the lever exclusivity-is-sold-as-a-window). A related-person transaction (overlapping leadership and equity), approved by a special committee.
The payer's own page, Tempus AI, Inc. (SEC Form 8-K, Item 8.01, 23 October 2026)
$100 per delivered recordper delivered de-identified patient record
Licensing deals
- Oct 2026Tempus AI to Pathos AI$55M
Not stated
In the same deals and cases
Cite this
AIData.Broker, “Pathos AI in the AI training data market”, reviewed 23 Oct 2026. https://aidata.broker/companies/pathos-ai
Free to reuse under CC BY 4.0 if you credit AIData.Broker and link to this page. Each row names the publication that stated it, and words quoted from a source keep that source's own terms.